Hemofiltration Parameter Modeling for α-Synuclein Aggregate Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack an effective way to clear α-synuclein aggregates in patients with neurodegenerative diseases, which contribute to immune disorders and neuroinflammation, as existing hemofiltration parameters are not tailored to the varying molecular forms of α-synuclein, particularly dimers and polymers, leading to insufficient clearance.
Innovation Solution
A modified hemofiltration method is developed, using a calculation model to determine the exchange membrane aperture based on the ratio of α-synuclein dimers, incorporating blood flow velocity and membrane area, to achieve targeted clearance of peripheral α-synuclein aggregates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If standard hemofiltration parameters are used, then the procedure is simple and easy to operate, but the clearance rate of α-synuclein aggregates is insufficient
Solution Approach 1:
The patent applies parameter changes by establishing a calculation model that determines exchange membrane aperture based on the ratio of α-synuclein dimers. The model uses the formula D=5.44S+1.7376, where D is the exchange membrane aperture and S is the ratio of α-synuclein dimers. This transforms the fixed parameter approach into a dynamic parameter adjustment strategy, optimizing clearance efficiency for different patient conditions while maintaining operational feasibility through standardized calculation procedures.
2Manufacturing precision
If hemofiltration parameters are tailored to individual α-synuclein profiles, then clearance efficiency is improved, but the procedure becomes more complex and time-consuming
Solution Approach 1:
The patent implements preliminary action by pre-establishing the calculation model D=5.44S+1.7376 based on linear regression analysis of clinical data. This model is developed beforehand and can be directly applied to individual patients without requiring complex real-time optimization. The blood flow velocity and exchange membrane area are also predetermined based on clinical trial data, allowing rapid parameter determination when a patient undergoes hemofiltration, thus reducing the time loss while maintaining precise clearance.
3Productivity
If a calculation model is built to determine exchange membrane aperture, then the clearance rate increases to 20±2%, but the device and process complexity increases
Solution Approach 1:
The patent applies mechanics substitution by replacing complex mechanical or empirical parameter adjustment methods with a mathematical calculation model. Instead of relying on trial-and-error or complex multi-parameter optimization, the invention uses the straightforward linear formula D=5.44S+1.7376 to determine the exchange membrane aperture. This substitution achieves the desired 20±2% clearance rate while keeping the implementation relatively simple, as it only requires measuring the ratio of α-synuclein dimers and applying the formula.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves a clearance rate of 20±2% for peripheral α-synuclein aggregates, effectively relieving symptoms of α-synuclein-related toxicity and reducing the risk of neurodegenerative diseases by personalizing hemofiltration parameters.
Implementation Method 1
Hemofiltration (HF) is a technique by which a certain amount of replacement fluid is continuously replenished in a vascular access and mixed well with blood for ultrafiltration at the same rate to clear excess water and toxins from body
Implementation Method 2
analyzing a correlation between the ratio S of the α-synuclein dimers and an exchange membrane aperture D required for hemofiltration by linear regression, and building a calculation model for the ratio S and the exchange membrane aperture D
Data Source
AI summary
A modified hemofiltration method for clearing peripheral α-synuclein aggregates in patients with neurodegenerative diseases is provided, which falls into the field of medicine. Specifically, a ratio S of synuclein dimers in blood is obtained; a blood flow velocity and an exchange membrane area for hemofiltration are determined through clinical trial data or historical literature data; hemofiltration is performed by the determined blood flow velocity and exchange membrane area, a calculation model of the ratio S of different synuclein dimers and an exchange membrane aperture D required for hemofiltration is constructed by linear regression; a clearance rate of synuclein dimers can be estimated by setting hemofiltration parameters with the calculation model. It is found that hemofiltration is beneficial to reducing the level of peripheral α-synuclein aggregates in patients with neurodegenerative diseases. Therefore, the calculation model is constructed, which provides scientific data and a new solution for clinically relieving α-synuclein-related toxicity symptoms.